Literature DB >> 20058037

BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Alessandra Bizzarro1, V Guglielmi, R Lomastro, A Valenza, A Lauria, C Marra, M C Silveri, F D Tiziano, C Brahe, C Masullo.   

Abstract

Alzheimer's disease (AD) is characterized by a significant reduction in AcetylCholinesterase and an increase in ButyrylCholinesterase (BuChE) activity. The existence of polymorphic regions on the BuChE gene has been previously described; the most frequently found polymorphism is the so-called K variant, which leads to a 30% decreased enzymatic activity. Different studies reported a positive association between K variant and AD, strongest among late-onset AD and Apolipoprotein E (APOE) e4 carriers. We analyzed APOE and BuChE polymorphisms in 167 AD and 59 fronto-temporal dementia (FTD) patients compared with 129 healthy controls (HC). We reported a significantly lower frequency of the BuChE K variant in AD compared with HC and FTD and a significant increased frequency of the K variant in FTD. These results are in agreement with the known increase of the BuChE activity in AD and support the evidence of different molecular pathways involved in the pathogenesis of AD and FTD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20058037     DOI: 10.1007/s00702-009-0358-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  47 in total

1.  Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils.

Authors:  A Alvarez; C Opazo; R Alarcón; J Garrido; N C Inestrosa
Journal:  J Mol Biol       Date:  1997-09-26       Impact factor: 5.469

2.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

3.  DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.

Authors:  C F Bartels; F S Jensen; O Lockridge; A F van der Spek; H M Rubinstein; T Lubrano; B N La Du
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

4.  Butyrylcholinesterase attenuates amyloid fibril formation in vitro.

Authors:  Sophia Diamant; Erez Podoly; Assaf Friedler; Hagai Ligumsky; Oded Livnah; Hermona Soreq
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

5.  Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains.

Authors:  Estifanos Ghebremedhin; Dietmar R Thal; Christian Schultz; Heiko Braak
Journal:  Neurosci Lett       Date:  2002-03-01       Impact factor: 3.046

6.  Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.

Authors:  C Holmes; C Ballard; D Lehmann; A David Smith; H Beaumont; I N Day; M Nadeem Khan; S Lovestone; M McCulley; C M Morris; D G Munoz; K O'Brien; C Russ; T Del Ser; D Warden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

7.  No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease.

Authors:  A B Singleton; G Smith; A M Gibson; R Woodward; R H Perry; P G Ince; J A Edwardson; C M Morris
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

8.  Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.

Authors:  Asad Vaisi Raygani; Mahine Zahrai; Akbar Soltanzadeh; Mahmood Doosti; Ebrahim Javadi; Tayebeh Pourmotabbed
Journal:  Neurosci Lett       Date:  2004-11-23       Impact factor: 3.046

9.  Alzheimer's disease: case-control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample.

Authors:  Mariapaola Piccardi; Donatella Congiu; Alessio Squassina; Francesca Manconi; Paolo Francesco Putzu; Rosa Maria Mereu; Caterina Chillotti; Maria Del Zompo
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-10-05       Impact factor: 3.568

10.  Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients.

Authors:  P Gómez-Ramos; C Bouras; M A Morán
Journal:  Brain Res       Date:  1994-03-21       Impact factor: 3.252

View more
  4 in total

1.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

2.  Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.

Authors:  Sophie Sokolow; Xiaohui Li; Lucia Chen; Kent D Taylor; Jerome I Rotter; Robert A Rissman; Paul S Aisen; Liana G Apostolova
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.160

3.  Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.

Authors:  Zongcheng Wang; Yuren Jiang; Xi Wang; Yangsen Du; Dandan Xiao; Youchao Deng; Jinlian Wang
Journal:  Med Sci Monit       Date:  2015-05-16

4.  Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients.

Authors:  Natsalil Pongthanaracht; Somchai Yanarojana; Darawan Pinthong; Supeenun Unchern; Amnuay Thithapandha; Prasert Assantachai; Porntip Supavilai
Journal:  Clin Interv Aging       Date:  2017-05-26       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.